Shares of GRAIL, Inc. (NASDAQ:GRAL - Get Free Report) saw an uptick in trading volume on Monday . 1,089,746 shares were traded during mid-day trading, a decline of 14% from the previous session's volume of 1,267,568 shares.The stock last traded at $91.69 and had previously closed at $78.00.
Wall Street Analyst Weigh In
Several research firms recently weighed in on GRAL. Canaccord Genuity Group lifted their price target on shares of GRAIL from $43.00 to $75.00 and gave the company a "buy" rating in a report on Friday, October 3rd. Weiss Ratings restated a "sell (d-)" rating on shares of GRAIL in a report on Wednesday, October 8th. Finally, UBS Group set a $75.00 target price on shares of GRAIL in a report on Friday, October 3rd. One equities research analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of "Hold" and a consensus target price of $56.67.
Check Out Our Latest Analysis on GRAL
GRAIL Stock Performance
The firm has a 50-day moving average price of $46.19 and a 200-day moving average price of $40.29. The stock has a market cap of $3.31 billion, a PE ratio of -7.00 and a beta of 4.11.
GRAIL (NASDAQ:GRAL - Get Free Report) last posted its quarterly earnings results on Tuesday, August 12th. The company reported ($3.18) earnings per share (EPS) for the quarter, missing the consensus estimate of ($3.14) by ($0.04). GRAIL had a negative return on equity of 16.64% and a negative net margin of 329.86%.The company had revenue of $35.54 million during the quarter, compared to analysts' expectations of $37.57 million. As a group, sell-side analysts anticipate that GRAIL, Inc. will post -15.15 EPS for the current fiscal year.
Insider Activity
In other news, President Joshua J. Ofman sold 6,114 shares of the company's stock in a transaction dated Thursday, October 16th. The shares were sold at an average price of $82.01, for a total transaction of $501,409.14. Following the completion of the sale, the president owned 381,818 shares of the company's stock, valued at $31,312,894.18. This represents a 1.58% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Robert P. Ragusa sold 7,239 shares of the business's stock in a transaction that occurred on Wednesday, October 15th. The shares were sold at an average price of $68.88, for a total value of $498,622.32. Following the transaction, the chief executive officer owned 727,388 shares of the company's stock, valued at approximately $50,102,485.44. This trade represents a 0.99% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 117,497 shares of company stock valued at $7,515,436 in the last ninety days.
Institutional Inflows and Outflows
Hedge funds have recently made changes to their positions in the stock. Farther Finance Advisors LLC grew its stake in shares of GRAIL by 768.1% during the 2nd quarter. Farther Finance Advisors LLC now owns 816 shares of the company's stock valued at $42,000 after acquiring an additional 722 shares during the period. Roble Belko & Company Inc bought a new position in GRAIL in the 2nd quarter worth approximately $68,000. Cypress Capital Management LLC WY bought a new position in GRAIL in the 2nd quarter worth approximately $72,000. KBC Group NV boosted its stake in GRAIL by 187.7% in the 1st quarter. KBC Group NV now owns 1,430 shares of the company's stock worth $37,000 after purchasing an additional 933 shares during the period. Finally, S.A. Mason LLC boosted its stake in GRAIL by 50.1% in the 1st quarter. S.A. Mason LLC now owns 1,499 shares of the company's stock worth $38,000 after purchasing an additional 500 shares during the period.
GRAIL Company Profile
(
Get Free Report)
GRAIL, Inc operates as a commercial-stage healthcare company, which engages in the development of a technology for early detection of cancer. It utilizes machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. The company was founded by Jeffrey T.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider GRAIL, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and GRAIL wasn't on the list.
While GRAIL currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
